InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by ANDREWS RONALD ASBURY, Director. Director active across 2 companies, notably Precipio, Inc.. Aggregated, 7 disclosures have been logged. Total volume traded: €58k. The latest transaction was filed on 15 October 2025 — Attribution. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations7 total
US$8,574568 shares@ US$15.09490.018% mcap100.0% of flow
Common Stock
SEC:0001104659-26-005081·
€8,574568 shares@ €15.09490.018% mcap50.0% of flow
Common Stock
SEC:0001104659-26-005081:0·
€58,48150,000 shares@ €1.1696100.0% of flow
Common Stock, no par value
SEC:0001493152-22-007205:0·
Ideal exit: 11 Dec 2022 (T+270)
065,000 shares0
Common Stock, no par value
SEC:0001493152-21-016130·
0106,221 shares0
Common Stock, no par value
SEC:0001493152-21-015984·
065,000 shares0
Common Stock, no par value
SEC:0001493152-21-016130:0·
0106,221 shares0
Common Stock, no par value
SEC:0001493152-21-015984:0·
7 of 7 declarations
About ANDREWS RONALD ASBURY
Ronald Asbury Andrews serves as Chief Executive Officer and Director at Precipio, Inc. and OncoCyte Corp. He leads the strategic operations of both companies, focusing on growth and innovation. Ronald has extensive experience in the sector, enabling him to effectively guide teams toward achieving organizational goals. His leadership is essential for the future development of the companies.
